CA2 and pancreatic neoplasm: Contrastingly, a study from Poland showed the low sensitivity and specificity of anti-CA II (45.3% and 74.3%, respectively, at a cutoff of 38.4 ng/ml), which was increased not only in patients with CP but also in patients with pancreatic cancer.